Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free MRUS Stock Alerts $39.81 -0.66 (-1.63%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$39.27▼$42.3850-Day Range$39.81▼$51.8252-Week Range$18.21▼$52.03Volume795,015 shsAverage Volume571,636 shsMarket Capitalization$2.34 billionP/E RatioN/ADividend YieldN/APrice Target$56.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Merus alerts: Email Address Merus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside41.5% Upside$56.33 Price TargetShort InterestHealthy5.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.29) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.94 out of 5 starsMedical Sector372nd out of 911 stocksPharmaceutical Preparations Industry162nd out of 411 stocks 4.5 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.86% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Merus has recently decreased by 16.10%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 2.7 News and Social Media Coverage News SentimentMerus has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Merus this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.29) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -13.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -13.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIStart loving Mondays like thisWouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!Weekend after weekend! About Merus Stock (NASDAQ:MRUS)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesApril 13, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Stock Rating Reaffirmed by Needham & Company LLCApril 10, 2024 | investing.comMerus reports progress on cancer therapy at AACR meetingApril 19, 2024 | DTI (Ad)Don’t expose yourself to stocks during the weekThe S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.April 8, 2024 | finanznachrichten.deMerus N.V.: Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024April 8, 2024 | globenewswire.comMerus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024April 3, 2024 | finance.yahoo.comMerus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 11, 2024 | finance.yahoo.comMRUS Dec 2024 50.000 callMarch 10, 2024 | finance.yahoo.comMRUS Jan 2025 50.000 putApril 19, 2024 | DTI (Ad)Don’t expose yourself to stocks during the weekThe S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.March 9, 2024 | finance.yahoo.comMRUS Apr 2024 35.000 putMarch 9, 2024 | finance.yahoo.comMRUS Apr 2024 40.000 callMarch 6, 2024 | marketwatch.comGilead, Merus to Collaborate on Trispecific Antibody ResearchMarch 6, 2024 | msn.comGilead to invest in Merus as part of a research dealMarch 6, 2024 | finance.yahoo.comMerus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionMarch 6, 2024 | finance.yahoo.comGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersMarch 5, 2024 | finance.yahoo.comMerus Full Year 2023 Earnings: Misses ExpectationsMarch 4, 2024 | markets.businessinsider.comStrong Buy Rating for Merus’s Peto: Anticipating High Market Potential and Synergistic Treatment EfficacyMarch 2, 2024 | finance.yahoo.comEarnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported And Analysts Are Trimming Their ForecastsMarch 1, 2024 | seekingalpha.comMerus: Positive Zenocutuzumab Data In 2024 Could Provide BLA AdvancementMarch 1, 2024 | markets.businessinsider.comMerus’s Upgraded Outlook: Buy Rating and Price Target Boost Amid Promising Drug Trials and Financial StabilityFebruary 29, 2024 | finance.yahoo.comMRUS Apr 2024 40.000 putFebruary 29, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Merus (MRUS)February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed on Merus’s Stock Amid Strong Clinical Developments and Market PotentialFebruary 28, 2024 | finanznachrichten.deMerus N.V.: Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateFebruary 28, 2024 | globenewswire.comMerus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateFebruary 16, 2024 | finance.yahoo.comMRUS Mar 2024 40.000 callFebruary 16, 2024 | finance.yahoo.comMRUS Sep 2024 55.000 callSee More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees172Year FoundedN/APrice Target and Rating Average Stock Price Target$56.33 High Stock Price Target$69.00 Low Stock Price Target$45.00 Potential Upside/Downside+41.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-352.56% Pretax Margin-345.30% Return on Equity-50.61% Return on Assets-37.56% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual Sales$43.95 million Price / Sales53.16 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book6.45Miscellaneous Outstanding Shares58,690,000Free Float56,164,000Market Cap$2.34 billion OptionableOptionable Beta1.10 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 61)CEO, President & Executive Director Comp: $953.06kMr. Gregory D. Perry (Age 64)Chief Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 46)EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 57)Chief Business Officer, Executive VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Senior VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 59)CTO & Executive VP Comp: $350.85kDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPKathleen FarrenIR & Corporate Communications OfficerMore ExecutivesKey CompetitorsVera TherapeuticsNASDAQ:VERARhythm PharmaceuticalsNASDAQ:RYTMCorcept TherapeuticsNASDAQ:CORTArvinasNASDAQ:ARVNSummit TherapeuticsNASDAQ:SMMTView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 1,590 shares on 4/18/2024Ownership: 0.003%Medicxi Ventures Management Jersey LtdSold 430,972 shares on 4/15/2024Ownership: 1.992%Vanguard Group Inc.Sold 27,093 shares on 3/11/2024Ownership: 0.263%Wellington Management Group LLPSold 725,844 shares on 3/5/2024Ownership: 3.472%Goldman Sachs Group Inc.Bought 180,967 shares on 3/1/2024Ownership: 0.670%View All Insider TransactionsView All Institutional Transactions MRUS Stock Analysis - Frequently Asked Questions Should I buy or sell Merus stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks. What is Merus' stock price target for 2024? 10 analysts have issued 1-year price targets for Merus' shares. Their MRUS share price targets range from $45.00 to $69.00. On average, they expect the company's share price to reach $56.33 in the next year. This suggests a possible upside of 41.5% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts. How have MRUS shares performed in 2024? Merus' stock was trading at $27.50 on January 1st, 2024. Since then, MRUS shares have increased by 44.8% and is now trading at $39.81. View the best growth stocks for 2024 here. When is Merus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MRUS earnings forecast. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) released its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.38. The biotechnology company had revenue of $8.94 million for the quarter, compared to analysts' expectations of $10.43 million. Merus had a negative net margin of 352.56% and a negative trailing twelve-month return on equity of 50.61%. What ETFs hold Merus' stock? ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).BlackRock Future Health ETF (BMED). What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC). When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Medicxi Ventures Management Jersey Ltd (1.99%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRUS) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle PublishingHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving TrendsUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.